NCT07532655
A Single Ascending Dose and Multiple Ascending Doses Study of SYH2082 Injection in Healthy Participants
StatusRecruiting
PhasePhase 1
Primary completion (estimated)
At risk: Primary completion moved at least 3 months later.
See at-risk trials from CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗
Notable Recruitment opened Show 8 more changesShow less
- Eligibility criteria expanded, about 198 words
- Primary completion pushed from Oct 28, 2026 to Jan 30, 2027
- Enrollment increased: 44 → 60 participants
- Study completion pushed from Feb 9, 2027 to May 9, 2027
- Study sites: 0 to 1
- Start date changed from estimate of Apr 14, 2026 to Apr 10, 2026
- Secondary endpoints: details revised at 15 of 15 entries
- Study title expanded, about 4 words
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Number of Adverse Events as a measure of safety and tolerability of SYH2082
Timeframe: SAD: Screening period up to day 57 MAD: Screening period up to day 85
Secondary (15)
Maximum plasma concentration (Cmax)
Area under the concentration-time curve from time 0 to the last measurable time point (AUClast)
Area under the concentration time curve from time 0 to infinity (AUCinf)
Time to maximum concentration (Tmax)
Elimination half-life (t1/2)
Show 10 moreShow less
Apparent volume of distribution (Vz/F)
Apparent clearance (CL/F)
Anti-SYH2082 antibodies
Change in fasting plasma glucose from baseline
Change in fasting insulin from baseline
Change in C-peptide from baseline
Change in glucagon from baseline
Change in body weight from baseline
Change in waist circumference from baseline
Corrected QT(QTc) interval
Arms and interventions
SYH2082 InjectionExperimental
Single-ascending dose and multiple-dose doses
PlaceboPlacebo comparator
Conduct in accordance with the study protocol.
Drugs: SYH2082 Injection, Placebo
Sites
1 site in 1 country
- Linear Clinical ResearchNedlands, Western Australia, Australia